Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Over-expression of deubiquitinating enzyme USP14 in lung adenocarcinoma promotes proliferation through the accumulation of β-catenin.

Wu N, Liu C, Bai C, Han YP, Cho WC, Li Q.

Int J Mol Sci. 2013 May 23;14(6):10749-60. doi: 10.3390/ijms140610749.

2.

MiR-4782-3p inhibited non-small cell lung cancer growth via USP14.

Wu N, Zhang C, Bai C, Han YP, Li Q.

Cell Physiol Biochem. 2014;33(2):457-67. doi: 10.1159/000358626. Epub 2014 Feb 11.

3.

Overexpression of deubiquitinating enzyme USP28 promoted non-small cell lung cancer growth.

Zhang L, Xu B, Qiang Y, Huang H, Wang C, Li D, Qian J.

J Cell Mol Med. 2015 Apr;19(4):799-805. doi: 10.1111/jcmm.12426. Epub 2015 Feb 5.

4.

Function of Deubiquitinating Enzyme USP14 as Oncogene in Different Types of Cancer.

Zhu Y, Zhang C, Gu C, Li Q, Wu N.

Cell Physiol Biochem. 2016;38(3):993-1002. doi: 10.1159/000443051. Epub 2016 Mar 4.

5.

DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.

Wang Z, Luo Z, Zhou L, Li X, Jiang T, Fu E.

Cancer Sci. 2015 Oct;106(10):1303-12. doi: 10.1111/cas.12755. Epub 2015 Sep 3.

6.

Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer.

Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X, Song Y.

PLoS One. 2012;7(4):e35065. doi: 10.1371/journal.pone.0035065. Epub 2012 Apr 6.

7.

Potential prognostic marker ubiquitin carboxyl-terminal hydrolase-L1 does not predict patient survival in non-small cell lung carcinoma.

Orr KS, Shi Z, Brown WM, O'Hagan KA, Lappin TR, Maxwell P, Percy MJ.

J Exp Clin Cancer Res. 2011 Aug 30;30:79. doi: 10.1186/1756-9966-30-79.

8.

Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor--an expression in non-small-cell lung cancer.

Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H, Ueno M.

J Clin Oncol. 2005 Dec 1;23(34):8765-73.

PMID:
16314637
9.

HBP1 promoter methylation augments the oncogenic β-catenin to correlate with prognosis in NSCLC.

Tseng RC, Huang WR, Lin SF, Wu PC, Hsu HS, Wang YC.

J Cell Mol Med. 2014 Sep;18(9):1752-61. doi: 10.1111/jcmm.12318. Epub 2014 Jun 4.

10.

Downregulation of ubiquitin-specific protease 14 (USP14) inhibits breast cancer cell proliferation and metastasis, but promotes apoptosis.

Zhu L, Yang S, He S, Qiang F, Cai J, Liu R, Gu C, Guo Z, Wang C, Zhang W, Zhang C, Wang Y.

J Mol Histol. 2016 Feb;47(1):69-80. doi: 10.1007/s10735-015-9650-3. Epub 2015 Dec 28.

PMID:
26712154
11.

Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing.

Basseres DS, D'Alò F, Yeap BY, Löwenberg EC, Gonzalez DA, Yasuda H, Dayaram T, Kocher ON, Godleski JJ, Richards WG, Meyerson M, Kobayashi S, Tenen DG, Halmos B, Costa DB.

Lung Cancer. 2012 Jul;77(1):31-7. doi: 10.1016/j.lungcan.2012.01.011. Epub 2012 Feb 16.

12.

GSK3β overexpression indicates poor prognosis and its inhibition reduces cell proliferation and survival of non-small cell lung cancer cells.

Zeng J, Liu D, Qiu Z, Huang Y, Chen B, Wang L, Xu H, Huang N, Liu L, Li W.

PLoS One. 2014 Mar 11;9(3):e91231. doi: 10.1371/journal.pone.0091231. eCollection 2014.

13.

Nemo-like kinase (NLK) inhibits the progression of NSCLC via negatively modulating WNT signaling pathway.

Lv L, Wan C, Chen B, Li M, Liu Y, Ni T, Yang Y, Liu Y, Cong X, Mao G, Xue Q.

J Cell Biochem. 2014 Jan;115(1):81-92. doi: 10.1002/jcb.24635.

PMID:
23904219
14.

FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells.

Xu N, Zhang X, Wang X, Ge HY, Wang XY, Garfield D, Yang P, Song YL, Bai CX.

Acta Pharmacol Sin. 2012 May;33(5):675-81. doi: 10.1038/aps.2011.188. Epub 2012 Mar 26.

15.
16.

USP14 activation promotes tumor progression in hepatocellular carcinoma.

Huang G, Li L, Zhou W.

Oncol Rep. 2015 Dec;34(6):2917-24. doi: 10.3892/or.2015.4296. Epub 2015 Sep 21.

PMID:
26397990
17.

Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival.

Zhou CH, Ye LP, Ye SX, Li Y, Zhang XY, Xu XY, Gong LY.

J Exp Clin Cancer Res. 2012 Mar 3;31:18. doi: 10.1186/1756-9966-31-18.

18.

Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.

Xu W, Jiang K, Shen M, Chen Y, Huang HY.

Oncol Rep. 2016 Jan;35(1):352-8. doi: 10.3892/or.2015.4349. Epub 2015 Oct 26.

PMID:
26498874
19.

Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.

Miao Y, Wang L, Zhang X, Xu X, Jiang G, Fan C, Liu Y, Lin X, Yu J, Zhang Y, Wang E.

PLoS One. 2014 Nov 14;9(11):e112258. doi: 10.1371/journal.pone.0112258. eCollection 2014.

20.

Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer.

Yang YR, Zang SZ, Zhong CL, Li YX, Zhao SS, Feng XJ.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6929-35. eCollection 2014.

Supplemental Content

Support Center